Ipatasertib meets one of two primary endpoints in Phase III trial

Posted on June 19, 2020 by Sitemaster

According to a media release issued by Roche earlier this morning, the company’s investigational drug known as ipatasertib met one but not both of the two primary endpoints in a randomized, double-blind Phase III trial known as the IPATential150 trial. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | Leave a comment »

Is PTEN loss a risk factor for progression of men on active surveillance?

Posted on October 8, 2018 by Sitemaster

A newly published paper in the journal Prostate Cancer and Prostatic Diseases has explored the above question based on data from the Johns Hopkins active surveillance (AS) cohort of men with initially low- or very low-risk prostate cancer. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: , , , , , | 4 Comments »

Liquid biopsies and CTC assays — the scientific progress continues

Posted on November 11, 2015 by Sitemaster

A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate cancer (and in related clinical trials). … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , , , , | 2 Comments »

PTEN expression and risk for progressive disease in low-risk patients

Posted on July 1, 2013 by Sitemaster

A new paper by Cuzick and colleagues has suggested that loss of expression of the PTEN gene, which encodes for a protein known as phosphatase and tensin homologue (PTEN), may be significantly associated with heightened risk of progressive disease in a cohort of nominally low-risk patients. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , , | Leave a comment »

Gene copy number alteration analysis and risk for prostate cancer-specific mortality

Posted on April 22, 2013 by Sitemaster

A new study, to published shortly on-line in Cancer, suggests that significant alterations to the “copy numbers” of the PTEN and MYC genes in men with prostate cancer are strongly associated with risk for prostate cancer-specific mortality. … READ MORE …

Filed under: Diagnosis, Management, Risk | Tagged: , , , , , , , | 3 Comments »

PTEN, MAN2C1, and the identification of potentially aggressive forms of prostate cancer

Posted on May 7, 2012 by Sitemaster

A new article in Nature Communications has suggested that we may be able to specifically identify some aggressive forms of prostate cancer cells that come with high risk for metastatic prostate cancer even at low PSA levels and other less aggressive forms of prostate cancer cell. … READ MORE …

Filed under: Diagnosis, Drugs in development, Risk | Tagged: , , , , , | 1 Comment »

Could just three genes identify potentially lethal prostate cancer?

Posted on January 26, 2010 by Sitemaster

A new report from members of the Transatlantic Prostate Study Group has suggested that information about three specific genes may be sufficient to identify a high proportion of men with potentially lethal as opposed to indolent prostate cancer. … READ MORE …

Filed under: Diagnosis, Management, Risk, Treatment | Tagged: , , , , , | 5 Comments »

Prostate cancer news reports: Friday, May 22, 2009

Posted on May 22, 2009 by Sitemaster

Today’s news reports cover items on:

  • Gene expression and prostate cancer progression
  • Risk of complications from in-office prostate biopsy
  • Post-RALP voiding function
  • Urinary toxicities after IMRT-SIB
  • Drugs in development for CRPC … READ MORE …

Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: , , , , , , , , , , , | Leave a comment »